Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 16:9:89.
doi: 10.1186/1475-2840-9-89.

Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides

Silvio Romano  1 , Michele Di Mauro, Simona Fratini, Leonello Guarracini, Fabrizio Guarracini, Gianfranco Poccia, Maria Penco
Affiliations

Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides

Silvio Romano et al. Cardiovasc Diabetol. .

Abstract

Background: The aim of the present study was to verify whether BNP might detect pre-clinical diastolic dysfunction (LVDD) in type-2 diabetic patients.

Methods: One-hundred and twenty-seven consecutive outpatients with type-2 diabetes mellitus were enrolled into the study. Subjects with overt heart failure or NYHA class > 1, history of coronary artery disease, severe valvulopathy or chronic atrial fibrillation were excluded from the study. All patients underwent clinical evaluation, laboratory assessment of brain natriuretic peptide (BNP) and echocardiographic examination.

Results: No patients showed systolic impairment of left ventricular function, whereas diastolic dysfunction was detected in 53 (42%) cases (all impaired relaxation). Median BNP was 27 pg/ml without any significant difference between 76 patients with normal left ventricular function and 53 with diastolic dysfunction; in 54 (43%) patients showing HBA1C≥8 (uncontrolled diabetes) normal function was found in 32 and diastolic dysfunction in 22, with a significant difference of BNP at multivariate analysis (OR = 1.02, 95%CI = 1.05-1.09, p = 0.003). In uncontrolled diabetic cohort, BNP was a strong predictor for LVDD (OR = 2.7, 95%CI = 1.3-5.6, p = 0.006) along with the duration of diabetes (OR = 1.6, 95%CI = 1.1-2.9, p = 0.046). BNP > 25 pg/ml was a cut-off value with high accuracy to detect a LVDD.

Discussion: Early screening of high-risk patients for diabetic cardiomyopathy development might be useful to better control glycemic profile in order to reduce heart disease progression or even to reverse it

Conclusions: BNP could be a cheap, easy and useful tool to screen those ones with preclinical ventricular diastolic dysfunction in a subset of patients particularly prone to develop cardiovascular complications, like uncontrolled diabetic patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box-plots: BNP value according to absence or presence of diastolic dysfunction. Numeric data reported in the figure are median and interquartile range.
Figure 2
Figure 2
Box-plots: BNP value according to absence or presence of diastolic dysfunction, in uncontrolled diabetic cohort. Numeric data reported in the figure are median and interquartile range.
Figure 3
Figure 3
ROC curve: BNP is a good predictor for DD in out of control cohort.
See this image and copyright information in PMC

References

    1. Saunders J, Mathewkutty S, Drazner MH, McGuire DK. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz. 2008;33:184–90. doi: 10.1007/s00059-008-3115-3. Review. - DOI - PubMed
    1. Nichols GA, Gullion CM, Koro CE. et al.The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879–84. doi: 10.2337/diacare.27.8.1879. - DOI - PubMed
    1. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001;38:421–8. doi: 10.1016/S0735-1097(01)01408-5. - DOI - PubMed
    1. Jaarsma T, Van der Wal MH, Lesman-Leegte I. for the COACH Study Group et al.Effect of moderate or intensive disease management program on outcome in patients with heart failure. The Coordinating study evaluating Outcomes of Advising and Counseling in Heart failure (COACH) Arch Intern Med. 2008;168:316–24. doi: 10.1001/archinternmed.2007.83. - DOI - PubMed
    1. McMurray JJ, Teerlink JR, Cotter G. for the VERITAS Investigators et al.Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure. The VERITAS randomized controlled trials. JAMA. 2007;298:2009–19. doi: 10.1001/jama.298.17.2009. - DOI - PubMed

MeSH terms